Arrowhead Pharmaceuticals, Inc. (ARWR)
| Market Cap | 6.77B |
| Revenue (ttm) | 89.12M |
| Net Income (ttm) | -109.59M |
| Shares Out | 103.87M |
| EPS (ttm) | -1.07 |
| PE Ratio | n/a |
| Forward PE | 111.11 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 11 |
| Last Price | $69.81 |
| Previous Close | $66.10 |
| Change ($) | 3.71 |
| Change (%) | 5.61% |
| Day's Open | 64.15 |
| Day's Range | 63.50 - 71.13 |
| Day's Volume | 781,756 |
| 52-Week Range | 30.83 - 92.60 |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals today announced financial results for its fiscal second quarter ended March 31, 2021.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced positive interim 48-week liver biopsy results from the Phase 2 AROAAT2002 study evaluating ARO-AAT for rare genetic liver disease associated wi...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Announces Improvement in Fibrosis after ARO-AAT, being co-developed with Takeda, in Patients with the rare genetic Alpha-1 Liver Disease
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $ARWR--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead's first muscle targeted investigational RNAi therapeutic candidate to ut...
In Q4 2020, we discussed why Arrowhead stock, a biopharmaceutical company that develops RNA interference therapies, looks attractive despite a stellar 16x move since early 2018. The stock has had a vola...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead submitted an IND to the U.S. Food and Drug Administration for ARO-APOC3, an RNAi therapeutic for hypertriglyceridemia
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 566.67% over the past year to ($0.20)...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead reports fiscal 2021 first quarter earnings and holds a conference call
NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Arrowhead Pharmaceuticals, Inc. (NA...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead files IND for ARO-ANG3 to start Phase 2b study in patients with mixed dyslipidemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to release earnings and hold conference call on February 4 2021
ARWR is a leading RNAi therapeutics company with a vast pipeline and a decade-long history of research. Often, companies with a long history of research find themselves unable to protect their Intellect...
Seven nanotech stocks to buy have the potential to reward investors as innovation in the sector accelerates. The post 7 Nanotech Stocks To Buy With Huge Returns in Store appeared first on InvestorPlace.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference and 20th Gordon L. Snider Critical Issues Workshop
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead completes collaboration and license agreement with Takeda Pharmaceutical Company Limited
Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval for the treatment of primary hyperoxaluria type 1 t...
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q4 2020 Results - Earnings Call Transcript
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) decreased 2.49% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 536.36% over the past year...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced financial results for its fiscal year ended September 30, 2020
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive clinical data from multiple product candidates in its cardiometabolic pipeline at the American Heart Association
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive interim clinical data at The AASLD Liver Meeting Digital Experience
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will Participate in multiple Upcoming November 2020 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead will host KOL webinars on two investigational RNAi based cardiometabolic candidates ARO-APOC3 and ARO-ANG3
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will webcast its fiscal 2020 year end earnings
These biotechs are fueling up for massive market launches.
Despite a 3x growth since the March 18 lows of this year, at the current price of around $60 per share we believe Arrowhead (NASDAQ: ARWR), a biopharmaceutical company that develops RNA interference the...
Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma companies th...
Vertex's losses are Arrowhead's gains.
Arrowhead Pharmaceuticals establishes deal with Takeda for the use of ARO-AAT in a deal worth up to $1.04 billion.
Arrowhead's New Deal With Takeda Strengthens The Company's Value Proposition
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to participate in Chardan Genetic Medicines Conference
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead reports inducement grants
Arrowhead Pharmaceuticals (ARWR) news for Wednesday includes positive interim results from a clinical trial pushing ARWR stock higher. The post Arrowhead Pharmaceuticals News: Why ARWR Stock Is Shooting...
Arrowhead Pharma posted positive clinical trials data on a promising drug to treat a rare genetic liver disease, and ARWR stock soared near a nine-moth high; shares of rival Dicerna also jumped. The pos...
The company reported positive interim data from a clinical trial.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has announced positive interim 24-week liver biopsy results in four subjects from its midstage study of ARO-AAT.
Arrowhead Pharmaceuticals Is A Smart Long-Term Opportunity
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead appoints veteran pharmaceutical industry executive Oye Olukotun, M.D.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to present at multiple investor conferences in September 2020
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead and Janssen present Phase clinical data on hepatitis B treatment JNJ-3989 at EASL International Liver Congress 2020
Arrowhead Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post IBD Rating Upgrades: Arrowhead Pharma Shows Improved Relative Price Strength appeared fir...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to present at August 2020 conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead dosed the first patient in a clinical trial of RNAi based ARO-HIF2 for treatment of renal cell carcinoma
BioBoyScout recently raised his price target on Arrowhead Pharmaceuticals to $107.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis
Most Medical Development & Treatment companies tend not to be involved in the Covid-19 virus vaccine race.
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2020 Results - Earnings Call Transcript
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clin... [Read more...]
| Industry Biotechnology | IPO Date Jun 16, 1993 |
| CEO Christopher Anzalone | Employees 232 |
| Stock Exchange NASDAQ | Ticker Symbol ARWR |
Analyst Forecasts
According to 12 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is 91.08, which is an increase of 30.47% from the latest price.